Free Trial
NASDAQ:PHIO

Phio Pharmaceuticals (PHIO) Stock Price, News & Analysis

Phio Pharmaceuticals logo
$2.27 -0.20 (-8.10%)
Closing price 06/13/2025 04:00 PM Eastern
Extended Trading
$2.28 +0.00 (+0.22%)
As of 06/13/2025 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Phio Pharmaceuticals Stock (NASDAQ:PHIO)

Key Stats

Today's Range
$2.20
$2.47
50-Day Range
$1.01
$2.96
52-Week Range
$0.97
$9.79
Volume
262,924 shs
Average Volume
2.45 million shs
Market Capitalization
$10.89 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$14.00
Consensus Rating
Buy

Company Overview

Phio Pharmaceuticals Corp. engages in the development of immuno-oncology therapeutics in the United States. The company is developing PH-762, an INTASYL compound in Phase 1b dose-escalating clinical trials to reduce the expression of cell death protein 1 (PD-1), a protein that inhibits T cells' ability to kill cancer cells; and PH-762 treated double positive tumor infiltrating lymphocytes, which is in Phase 1 clinical trials to treat advanced melanoma and other advanced solid tumors. It is also developing PH-894, an INTASYL compound in IND enabling studies to silence BRD4, a protein that controls gene expression in both T cells and tumor cells, effecting the immune system and the tumor. The company was formerly known as RXi Pharmaceuticals Corporation and changed its name to Phio Pharmaceuticals Corp. in November 2018. Phio Pharmaceuticals Corp. was incorporated in 2011 and is based in Marlborough, Massachusetts.

Phio Pharmaceuticals Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
79th Percentile Overall Score

PHIO MarketRank™: 

Phio Pharmaceuticals scored higher than 79% of companies evaluated by MarketBeat, and ranked 220th out of 938 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Phio Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Phio Pharmaceuticals has only been the subject of 1 research reports in the past 90 days.

  • Read more about Phio Pharmaceuticals' stock forecast and price target.
  • Earnings Growth

    Earnings for Phio Pharmaceuticals are expected to grow in the coming year, from ($8.54) to $3.76 per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Phio Pharmaceuticals is -0.21, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Phio Pharmaceuticals is -0.21, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Phio Pharmaceuticals has a P/B Ratio of 0.12. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

  • Read more about Phio Pharmaceuticals' valuation and earnings.
  • Percentage of Shares Shorted

    4.79% of the float of Phio Pharmaceuticals has been sold short.
  • Short Interest Ratio / Days to Cover

    Phio Pharmaceuticals has a short interest ratio ("days to cover") of 0.1, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Phio Pharmaceuticals has recently decreased by 45.06%, indicating that investor sentiment is improving significantly.
  • Dividend Yield

    Phio Pharmaceuticals does not currently pay a dividend.

  • Dividend Growth

    Phio Pharmaceuticals does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    4.79% of the float of Phio Pharmaceuticals has been sold short.
  • Short Interest Ratio / Days to Cover

    Phio Pharmaceuticals has a short interest ratio ("days to cover") of 0.1, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Phio Pharmaceuticals has recently decreased by 45.06%, indicating that investor sentiment is improving significantly.
  • News Sentiment

    Phio Pharmaceuticals has a news sentiment score of 1.03. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.89 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 8 news articles for Phio Pharmaceuticals this week, compared to 0 articles on an average week.
  • Search Interest

    2 people have searched for PHIO on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days.
  • MarketBeat Follows

    7 people have added Phio Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is an increase of 75% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Phio Pharmaceuticals insiders have bought more of their company's stock than they have sold. Specifically, they have bought $22,461.00 in company stock and sold $0.00 in company stock.

  • Percentage Held by Insiders

    Only 0.59% of the stock of Phio Pharmaceuticals is held by insiders.

  • Percentage Held by Institutions

    57.31% of the stock of Phio Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Phio Pharmaceuticals' insider trading history.
Receive PHIO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Phio Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

PHIO Stock News Headlines

FY2025 Earnings Forecast for PHIO Issued By HC Wainwright
Q2 Earnings Estimate for PHIO Issued By HC Wainwright
The End of Elon Musk…?
The End of Elon Musk? Don't make him laugh. Jeff Brown has been hearing this same tired story for years, and he's been proven right time and time again. And now, while the media focuses on Tesla's "demise," he's uncovered an AI breakthrough that's about to make Elon's doubters eat their words yet again. According to his research, if you listen to the media and miss out on Elon's newest breakthrough, it's going to cost you the fortune of a lifetime.
See More Headlines

PHIO Stock Analysis - Frequently Asked Questions

Phio Pharmaceuticals' stock was trading at $1.80 at the start of the year. Since then, PHIO stock has increased by 26.1% and is now trading at $2.27.
View the best growth stocks for 2025 here
.

Phio Pharmaceuticals Corp. (NASDAQ:PHIO) announced its quarterly earnings data on Wednesday, August, 14th. The company reported ($3.62) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($4.59) by $0.97.

Phio Pharmaceuticals's stock reverse split on Friday, July 5th 2024. The 1-9 reverse split was announced on Friday, July 5th 2024. The number of shares owned by shareholders was adjusted after the market closes on Friday, July 5th 2024. An investor that had 100 shares of stock prior to the reverse split would have 11 shares after the split.

Shares of PHIO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Phio Pharmaceuticals investors own include Zomedica (ZOM), Jumia Technologies (JMIA), Nano Dimension (NNDM), NIO (NIO), AST SpaceMobile (ASTS), Phunware (PHUN) and Virgin Galactic (SPCE).

Company Calendar

Last Earnings
8/14/2024
Today
6/15/2025
Next Earnings (Estimated)
8/13/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:PHIO
Employees
10
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$14.00
High Stock Price Target
$14.00
Low Stock Price Target
$14.00
Potential Upside/Downside
+516.7%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
1 Analysts

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$10.83 million
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Price / Cash Flow
N/A
Book Value
$18.57 per share
Price / Book
0.12

Miscellaneous

Free Float
6,847,000
Market Cap
$10.89 million
Optionable
Not Optionable
Beta
0.84
20 Stocks to Sell Now Cover

Today, we are inviting you to take a free peek at our proprietary, exclusive, and up-to-the-minute list of 20 stocks that Wall Street's top analysts hate.

Many of these appear to have good fundamentals and might seem like okay investments, but something is wrong. Analysts smell something seriously rotten about these companies. These are true "Strong Sell" stocks.

Get This Free Report

This page (NASDAQ:PHIO) was last updated on 6/16/2025 by MarketBeat.com Staff
From Our Partners